|
|
1787 Sentry Parkway West Bldg. 18 Suite 400
Blue Bell, PA 19422 USA
phone:267.440.4200
fax:267.440.4242
|
|
| Symbol |
INO |
| Exchange |
AMEX |
| Founded |
1983 |
| Employees |
40 |
|
|
| www.inovio.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| DNA vaccines to prevent and treat cancers and infectious diseases |
|
| Management |
| J. Joseph Kim, Ph.D., President, Chief Executive Officer, Director; Peter Kies, Chief Financial Officer; Mark L. Bagarazzi, Chief Medical Officer; Kevin W. Rassas, Senior Vice President, Business Development, President, VGX Animal Health; Niranjan Y. Sardesai, Ph.D., Senior Vice President, Research & Development |
| |
|
|
|
|
|
|
|
| Keywords |
| immunotherapies, pharmaceutical, genomic, influenza, antigenic |
|
|
|
| Description |
|
Inovio is focused on the design, development, and delivery of DNA vaccines to prevent and treat cancers and infectious diseases. Its SynCon(TM) technology enables the design of "universal" vaccines capable of protecting against known and emergent, unknown pathogen strains. Its electroporation delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio's clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. |
|
| Products / Services |
Inovio's proprietary/partnered DNA vaccine research includes:
- cervical cancer (therapeutic)
- HIV
- influenza (universal)
- hepatitis C virus
- various cancers
- dengue fever
- Chikungunya virus
|
|
| Technology / Differentiation |
| Inovio's proprietary electroporation technology has generated animal and human data showing the ability to enhance antibody and T-cell immune responses from DNA vaccines, rivaling alternative DNA delivery methods such as viral vectors. Its SynCon(TM) methodology enables the design of DNA vaccines with a synthetically-derived consensus of targeted antigens providing the ability to protect against multiple, unmatched strains of pathogens such as influenza and dengue fever. |
|
| Market / Customers |
Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH's Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network.
|
|
| Competitors / Substitutes / Alternatives |
-
|
|
| Strategy |
-
|
|
| Status |
| Inovio is conducting Phase I clinical studies for therapeutic cervical cancer vaccine, HIV, and has preclinical studies for influenza. Merck is conducting a Phase I for cancers expressing hTERT (breast, lung, prostate and others). Human data is expected from the cervical cancer study in Q2 and Q3. A Phase I for Inovio's H5N1 DNA vaccine is expected to begin in Q2 and for H1N1 in Q4. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
